Reduced alpha diversity of the oral microbiome correlates with short progression‐free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib‐based therapy (AGMT MM 1, phase II trial)

Abstract Alterations in the human microbiome have been linked to several malignant diseases. Here, we investigated the oral microbiome of 79 patients with relapsed/refractory multiple myeloma (MM) treated with ixazomib‐thalidomide‐dexamethasone. Increased alpha diversity (Shannon index) at the phylu...

Descripció completa

Dades bibliogràfiques

Autors principals:	Heinz Ludwig, Bela Hausmann, Martin Schreder, Wolfram Pönisch, Niklas Zojer, Stefan Knop, Eberhard Gunsilius, Alexander Egle, Andreas Petzer, Hermann Einsele, Roman Hajek, Katja Weisel, Karl Jochen Krenosz, Alois Lang, Daniel Lechner, Richard Greil, David Berry
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2021-02-01
Col·lecció:	eJHaem
Matèries:	molecular analysis mucosal multiple myeloma
Accés en línia:	https://doi.org/10.1002/jha2.130
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!